ABRAXANE Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
Abraxis BioScience, Inc. announced that the Office of Orphan Products Development of the food and Drug Administration (FDA) has granted Orphan Drug Designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.
“As we advance our pivotal clinical trials of ABRAXANE in pancreatic cancer and melanoma, we look forward to the potential of bringing a new treatment option to patients with these difficult to treat cancers,” said Lonnie Moulder, President and Chief Executive Officer.
Abraxis continues to study the potential of ABRAXANE in a variety of tumor types.
Other news from the department research and development

Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.